These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 14871963)

  • 1. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
    Curtin NJ; Wang LZ; Yiakouvaki A; Kyle S; Arris CA; Canan-Koch S; Webber SE; Durkacz BW; Calvert HA; Hostomsky Z; Newell DR
    Clin Cancer Res; 2004 Feb; 10(3):881-9. PubMed ID: 14871963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
    Calabrese CR; Almassy R; Barton S; Batey MA; Calvert AH; Canan-Koch S; Durkacz BW; Hostomsky Z; Kumpf RA; Kyle S; Li J; Maegley K; Newell DR; Notarianni E; Stratford IJ; Skalitzky D; Thomas HD; Wang LZ; Webber SE; Williams KJ; Curtin NJ
    J Natl Cancer Inst; 2004 Jan; 96(1):56-67. PubMed ID: 14709739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
    Liu L; Taverna P; Whitacre CM; Chatterjee S; Gerson SL
    Clin Cancer Res; 1999 Oct; 5(10):2908-17. PubMed ID: 10537360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
    Smith LM; Willmore E; Austin CA; Curtin NJ
    Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
    Thomas HD; Calabrese CR; Batey MA; Canan S; Hostomsky Z; Kyle S; Maegley KA; Newell DR; Skalitzky D; Wang LZ; Webber SE; Curtin NJ
    Mol Cancer Ther; 2007 Mar; 6(3):945-56. PubMed ID: 17363489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
    Horton TM; Jenkins G; Pati D; Zhang L; Dolan ME; Ribes-Zamora A; Bertuch AA; Blaney SM; Delaney SL; Hegde M; Berg SL
    Mol Cancer Ther; 2009 Aug; 8(8):2232-42. PubMed ID: 19671751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
    Wedge SR; Porteous JK; Newlands ES
    Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
    Tentori L; Portarena I; Torino F; Scerrati M; Navarra P; Graziani G
    Glia; 2002 Oct; 40(1):44-54. PubMed ID: 12237842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
    Cheng CL; Johnson SP; Keir ST; Quinn JA; Ali-Osman F; Szabo C; Li H; Salzman AL; Dolan ME; Modrich P; Bigner DD; Friedman HS
    Mol Cancer Ther; 2005 Sep; 4(9):1364-8. PubMed ID: 16170028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide: mechanisms of action, repair and resistance.
    Zhang J; Stevens MF; Bradshaw TD
    Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
    Tentori L; Muzi A; Dorio AS; Scarsella M; Leonetti C; Shah GM; Xu W; Camaioni E; Gold B; Pellicciari R; Dantzer F; Zhang J; Graziani G
    Curr Cancer Drug Targets; 2010 Jun; 10(4):368-83. PubMed ID: 20464779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
    Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
    Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.
    Goellner EM; Grimme B; Brown AR; Lin YC; Wang XH; Sugrue KF; Mitchell L; Trivedi RN; Tang JB; Sobol RW
    Cancer Res; 2011 Mar; 71(6):2308-17. PubMed ID: 21406402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.
    Tentori L; Portarena I; Vernole P; De Fabritiis P; Madaio R; Balduzzi A; Roy R; Bonmassar E; Graziani G
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):361-9. PubMed ID: 11345654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds.
    Tentori L; Turriziani M; Franco D; Serafino A; Levati L; Roy R; Bonmassar E; Graziani G
    Leukemia; 1999 Jun; 13(6):901-9. PubMed ID: 10360379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase.
    Tentori L; Lacal PM; Benincasa E; Franco D; Faraoni I; Bonmassar E; Graziani G
    J Pharmacol Exp Ther; 1998 May; 285(2):884-93. PubMed ID: 9580640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.
    Veuger SJ; Curtin NJ; Richardson CJ; Smith GC; Durkacz BW
    Cancer Res; 2003 Sep; 63(18):6008-15. PubMed ID: 14522929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
    Kyle S; Thomas HD; Mitchell J; Curtin NJ
    Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
    Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
    BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
    Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
    Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.